Cocrystal Pharma (NASDAQ: COCP) has announced that the scientific foundation and clinical progress of its lead pan-viral protease inhibitor, CDI-988, was discussed by President and CEO, Dr. Sam Lee, in a presentation at the 9th International Calicivirus Conference this week.
According to Cocrystal, CDI-988 is a potential first-ever oral antiviral for the prevention and treatment of norovirus infection. During the presentation, Dr. Lee emphasized CDI-988’s favorable safety profile in human intestinal tissue, the primary site of norovirus infection, along with its high exposure in the small intestine, suggesting a potential GI-targeted norovirus antiviral.
In a statement, Dr. Lee commented, “It was an honor to share highlights of our CDI-988 Phase 1 data with global norovirus experts at the leading calicivirus scientific meeting. The recent completion of Phase 1 study and FDA Investigation New Drug clearance for the next study mark significant milestones for our clinical development of CDI-988.”
